⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

Official Title: A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

Study ID: NCT02066285

Interventions

Pazopanib

Study Description

Brief Summary: Phase II, open-label, non-randomized, international multicenter clinical trial with two strata (SFT and EMC). 8 sites in Spain, 5 sites in Italy and 5 sites in France. Patients will receive oral pazopanib at 800 mg once daily continuously. Patients will continue to receive treatment until there is evidence of progressive disease, unacceptable toxicity, non-compliance, withdrawn consent or investigator decision. The main goal is to determine the objective response rate (ORR) (confirmed complete response \[CR\] and partial response \[PR\]) in patients with unresectable, locally advanced or metastatic solitary fibrous tumor and extraskeletal myxoid chondrosarcoma, using Choi and RECIST 1.1 criteria respectively.

Detailed Description: To estimate the sample size for stratum 1 (SFT), a Simon's optimal 2-stage phase II design has been used, having considered the published response rate based on Choi criteria in SFT patients which correspond to 40% in monotherapy. For a design with P0=0.40, P1=0.60; ι=0.1 and β=0.1. At the first stage, 18 patients should be enrolled into the study, if there are fewer than 8 responses (7 or less) the trial will be terminated and it will be concluded that pazopanib is not sufficiently active. At the second stage, another 28 patients (total 46 patients) would be enrolled into the study. To reject the null hypothesis for the SFT stratum 23 responses or more (Choi criteria), out of the 46 patients, are needed. To estimate the simple size for stratum 2 (EMC), a Simon's optimal 2-stage phase II design has been used, having considered the very scarce published information on response rate based on RECIST criteria. For a design with P0= 0.05, P1= 0.25, ι=0.1 and β=0.1. At the first stage, 9 patients should be enrolled into the study, if there are not responses the trial will be terminated and it will be concluded that pazopanib is not sufficiently active. If there is at least 1 response in this first stage, the trial will be continued and at the second stage, another 15 patients (total 24 patients) would be enrolled into the study. To reject the null hypothesis for the EMC stratum 3 responses or more (RECIST criteria), out of the 24 patients, are needed. For variables that follow binomial distributions (e.g. response rate) frequency and percentages will be calculated, together with their corresponding exact 95% confidence intervals. For time-to-event variables (e.g. PFS or OS) Kaplan-Meier estimations will be used. To analyze the reduction of risk and the influence of other variables on time-to-event variables Cox Regression will be applied. To correlate pharmacodynamics markers and biomarkers with clinical response standard methods for bivariate and multivariate regression and correlation will be used.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

H. Son Espases, Palma De Mallorca, Islas Baleares, Spain

H. Universitario de Canarias, Tenerife, Santa Cruz De Tenerife, Spain

Hospital de la Santa Creu i Sant Pau, Barcelona, , Spain

Hospital La Paz, Madrid, , Spain

Hospital RamĂłn y Cajal, Madrid, , Spain

Hospital Universitario Virgen del RocĂ­o, Sevilla, , Spain

H. Miguel Servet, Zaragoza, , Spain

Contact Details

Name: Josefina Cruz, MD

Affiliation: Hospital Universitario de Canarias

Role: STUDY_DIRECTOR

Name: Javier MartĂ­n, MD

Affiliation: Hospital Son Espases

Role: STUDY_DIRECTOR

Name: Antonio LĂłpez-Pousa, MD

Affiliation: Hospital Sant Pau

Role: PRINCIPAL_INVESTIGATOR

Name: M. Ángeles Vaz, MD

Affiliation: Hospital Universitario Ramon y Cajal

Role: PRINCIPAL_INVESTIGATOR

Name: AndrĂŠs Redondo, MD

Affiliation: Hospital La Paz

Role: PRINCIPAL_INVESTIGATOR

Name: Javier MartĂ­nez-Trufero, MD

Affiliation: Hospital Miguel Servet

Role: PRINCIPAL_INVESTIGATOR

Name: Pilar Blay, MD

Affiliation: Hospital Central de Asturias

Role: PRINCIPAL_INVESTIGATOR

Name: Pilar Sancho, MD

Affiliation: Hospital Virgen del RocĂ­o

Role: PRINCIPAL_INVESTIGATOR

Name: Jean Yves Blay, MD

Affiliation: Centre Leon Berard

Role: PRINCIPAL_INVESTIGATOR

Name: Silvia Stacchiotti, MD

Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: